Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if Mylan (Nasdaq: MYL) fits the bill.

The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
  • Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that company can turn revenue into profit.
  • Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
  • Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
  • Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.
  • Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at Mylan.


What We Want to See


Pass or Fail?

Growth 5-year annual revenue growth > 15% 36.2% Pass
  1-year revenue growth > 12% 7.6% Fail
Margins Gross margin > 35% 40.7% Pass
  Net margin > 15% 6.3% Fail
Balance sheet Debt to equity < 50% 150.9% Fail
  Current ratio > 1.3 1.97 Pass
Opportunities Return on equity > 15% 10.2% Fail
Valuation Normalized P/E < 20 21.86 Fail
Dividends Current yield > 2% 0% Fail
  5-year dividend growth > 10% 0% Fail
  Total Score   3 out of 10

Source: Capital IQ, a division of Standard & Poor's. Total score = number of passes.

Mylan only manages to come up with three points on our scale. The generic-drug manufacturer has seen some strong growth in recent years, but it faces a lot of competition in a tough industry.

As a maker of low-cost generics, Mylan is well-positioned for the new reality in health care. Big drug companies Merck (NYSE: MRK) and Eli Lilly (NYSE: LLY) face huge patent cliffs for their blockbuster drugs. Patent expirations threaten their ability to generate long-term revenue, but they represent huge potential opportunities for Mylan.

In addition, with the U.S. health-care reform law a year old, many expect generics to become even more important than they are currently, boosting Mylan's prospects along with those of peers Teva Pharmaceutical (Nasdaq: TEVA) and Dr. Reddy's Labs (NYSE: RDY).

Unfortunately, Mylan hasn't executed as well on its opportunities as some of its rivals. Teva has posted much stronger returns on equity and carries much less debt on its balance sheet, yet it trades at a cheaper valuation. Dr. Reddy's margins are also much higher than Mylan's. Because of its relatively small size, Mylan's earnings are also much bumpier than those of larger companies like Teva, making it difficult for risk-averse investors to stay the course.

Mylan is in a great industry. But until it starts living up to its potential, it's not going to be a perfect stock for your portfolio.

Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.

Click here to add Mylan to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Finding the perfect stock is only one piece of a successful investment strategy. Get the big picture by taking a look at our 13 Steps to Investing Foolishly.

Fool contributor Dan Caplinger doesn't own shares of the companies mentioned in this article. Dr. Reddy's Laboratories is a Motley Fool Global Gains pick. The Fool owns shares of Teva Pharmaceutical. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.